Image-guided Drug Delivery with Magnetic Resonance Guided High Intensity Focused Ultrasound and Temperature Sensitive Liposomes in a Rabbit Vx2 Tumor Model
Overview
Authors
Affiliations
Clinical-grade doxorubicin encapsulated low temperature sensitive liposomes (LTSLs) were combined with a clinical magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) platform to investigate in vivo image-guided drug delivery. Plasma pharmacokinetics were determined in 3 rabbits. Fifteen rabbits with Vx2 tumors within superficial thigh muscle were randomly assigned into three treatment groups: 1) free doxorubicin, 2) LTSL and 3) LTSL + MR-HIFU. For the LTSL + MR-HIFU group, mild hyperthermia (40-41 °C) was applied to the tumors using an MR-HIFU system. Image-guided non-invasive hyperthermia was applied for a total of 30 min, completed within 1h after LTSL infusion. High-pressure liquid chromatography (HPLC) analysis of the harvested tumor and organ/tissue homogenates was performed to determine doxorubicin concentration. Fluorescence microscopy was performed to determine doxorubicin spatial distribution in the tumors. Sonication of Vx2 tumors resulted in accurate (mean = 40.5 ± 0.1 °C) and spatially homogenous (SD = 1.0 °C) temperature control in the target region. LTSL + MR-HIFU resulted in significantly higher tumor doxorubicin concentrations (7.6- and 3.4-fold greater compared to free doxorubicin and LTSL respectively, p<0.05, Newman-Keuls). This improved tumor concentration was achieved despite heating <25% of the tumor volume. Free doxorubicin and LTSL treatments appeared to deliver more drug in the tumor periphery as compared to the tumor core. In contrast, LTSL + MR-HIFU treatment suggested an improved distribution with doxorubicin found in both the tumor periphery and core. Doxorubicin bio-distribution in non-tumor organs/tissues was fairly similar between treatment groups. This technique has potential for clinical translation as an image-guided method to deliver drug to a solid tumor.
Zubair M, Uddin I, Dickinson R, Diederich C Bioengineering (Basel). 2025; 12(1).
PMID: 39851288 PMC: 11760898. DOI: 10.3390/bioengineering12010014.
Liposomes for Cancer Theranostics.
Fernandes D Pharmaceutics. 2023; 15(10).
PMID: 37896208 PMC: 10610083. DOI: 10.3390/pharmaceutics15102448.
Spiers L, Gray M, Lyon P, Sivakumar S, Bekkali N, Scott S BMC Cancer. 2023; 23(1):896.
PMID: 37741968 PMC: 10517508. DOI: 10.1186/s12885-023-11228-z.
Ultrasound-Mediated Ocular Drug Delivery: From Physics and Instrumentation to Future Directions.
Duncan B, Al-Kassas R, Zhang G, Hughes D, Qiu Y Micromachines (Basel). 2023; 14(8).
PMID: 37630111 PMC: 10456754. DOI: 10.3390/mi14081575.
Physicochemical Stimulus-Responsive Systems Targeted with Antibody Derivatives.
Mohammadi R, Ghani S, Arezumand R, Farhadi S, Khazaee-Poul Y, Kazemi B Curr Mol Med. 2023; 24(10):1250-1268.
PMID: 37594115 DOI: 10.2174/1566524023666230818093016.